ZA200408776B - A DNA enzyme to inhibit plasminogen activator inhibitor-1 - Google Patents

Info

Publication number

ZA200408776B

ZA200408776B ZA200408776A ZA200408776A ZA200408776B ZA 200408776 B ZA200408776 B ZA 200408776B ZA 200408776 A ZA200408776 A ZA 200408776A ZA 200408776 A ZA200408776 A ZA 200408776A ZA 200408776 B ZA200408776 B ZA 200408776B

Authority

ZA

South Africa

Prior art keywords

subject

pai

disease

expression

pharmaceutical composition

Prior art date

2002-04-23

Links

• Espacenet
• Global Dossier
• Discuss

• 102000012335 Plasminogen Activator Inhibitor 1 Human genes 0.000 title claims abstract description 207
• 108010022233 Plasminogen Activator Inhibitor 1 Proteins 0.000 title claims abstract description 207
• 108020004414 DNA Proteins 0.000 title description 108
• 108090000790 Enzymes Proteins 0.000 title description 75
• 102000004190 Enzymes Human genes 0.000 title description 75
• 108020004999 messenger RNA Proteins 0.000 claims abstract description 107
• 238000000034 method Methods 0.000 claims abstract description 84
• 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 79
• 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 65
• 201000010099 disease Diseases 0.000 claims abstract description 55
• 239000003112 inhibitor Substances 0.000 claims abstract description 48
• 230000002401 inhibitory effect Effects 0.000 claims abstract description 22
• 239000000074 antisense oligonucleotide Substances 0.000 claims abstract description 21
• 238000012230 antisense oligonucleotides Methods 0.000 claims abstract description 21
• 239000002773 nucleotide Substances 0.000 claims description 100
• 125000003729 nucleotide group Chemical group 0.000 claims description 99
• 230000003197 catalytic effect Effects 0.000 claims description 98
• 150000007523 nucleic acids Chemical class 0.000 claims description 95
• 102000039446 nucleic acids Human genes 0.000 claims description 92
• 108020004707 nucleic acids Proteins 0.000 claims description 92
• 210000004027 cell Anatomy 0.000 claims description 58
• 108091034117 Oligonucleotide Proteins 0.000 claims description 53
• 230000027455 binding Effects 0.000 claims description 42
• 208000024172 Cardiovascular disease Diseases 0.000 claims description 39
• 108090000623 proteins and genes Proteins 0.000 claims description 28
• 210000004413 cardiac myocyte Anatomy 0.000 claims description 27
• 210000001519 tissue Anatomy 0.000 claims description 27
• 230000003176 fibrotic effect Effects 0.000 claims description 25
• 238000002347 injection Methods 0.000 claims description 25
• 239000007924 injection Substances 0.000 claims description 25
• 206010061216 Infarction Diseases 0.000 claims description 23
• 230000006907 apoptotic process Effects 0.000 claims description 22
• 208000034827 Neointima Diseases 0.000 claims description 21
• 210000002216 heart Anatomy 0.000 claims description 21
• 101000609255 Homo sapiens Plasminogen activator inhibitor 1 Proteins 0.000 claims description 20
• 238000002399 angioplasty Methods 0.000 claims description 20
• 230000008692 neointimal formation Effects 0.000 claims description 20
• 206010029113 Neovascularisation Diseases 0.000 claims description 19
• 108090000190 Thrombin Proteins 0.000 claims description 19
• 229960004072 thrombin Drugs 0.000 claims description 19
• 102000043283 human SERPINE1 Human genes 0.000 claims description 18
• 238000004519 manufacturing process Methods 0.000 claims description 18
• 125000002652 ribonucleotide group Chemical group 0.000 claims description 18
• 108010073385 Fibrin Proteins 0.000 claims description 17
• 102000009123 Fibrin Human genes 0.000 claims description 17
• BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 claims description 17
• 229950003499 fibrin Drugs 0.000 claims description 17
• -1 phenindone Chemical compound 0.000 claims description 16
• 230000005764 inhibitory process Effects 0.000 claims description 15
• 208000017169 kidney disease Diseases 0.000 claims description 15
• 208000019553 vascular disease Diseases 0.000 claims description 15
• 108091028664 Ribonucleotide Proteins 0.000 claims description 14
• 239000003795 chemical substances by application Substances 0.000 claims description 14
• 239000002336 ribonucleotide Substances 0.000 claims description 14
• 210000000329 smooth muscle myocyte Anatomy 0.000 claims description 14
• 210000000130 stem cell Anatomy 0.000 claims description 14
• 230000000295 complement effect Effects 0.000 claims description 12
• 125000002637 deoxyribonucleotide group Chemical group 0.000 claims description 12
• 239000003937 drug carrier Substances 0.000 claims description 12
• 230000004663 cell proliferation Effects 0.000 claims description 11
• 230000008021 deposition Effects 0.000 claims description 10
• 208000035475 disorder Diseases 0.000 claims description 10
• 239000003814 drug Substances 0.000 claims description 10
• 208000010125 myocardial infarction Diseases 0.000 claims description 10
• 241000124008 Mammalia Species 0.000 claims description 9
• 101000610236 Nostoc sp. (strain PCC 7120 / SAG 25.82 / UTEX 2576) Protein PatA Proteins 0.000 claims description 9
• 102100037882 Perilipin-5 Human genes 0.000 claims description 9
• 230000001939 inductive effect Effects 0.000 claims description 9
• 108090000435 Urokinase-type plasminogen activator Proteins 0.000 claims description 8
• 230000000747 cardiac effect Effects 0.000 claims description 8
• 239000005547 deoxyribonucleotide Substances 0.000 claims description 8
• 230000007574 infarction Effects 0.000 claims description 8
• 208000023589 ischemic disease Diseases 0.000 claims description 8
• 208000019423 liver disease Diseases 0.000 claims description 8
• 208000037803 restenosis Diseases 0.000 claims description 8
• 208000005764 Peripheral Arterial Disease Diseases 0.000 claims description 7
• 208000030831 Peripheral arterial occlusive disease Diseases 0.000 claims description 7
• 102000003990 Urokinase-type plasminogen activator Human genes 0.000 claims description 7
• 239000012190 activator Substances 0.000 claims description 7
• 208000009190 disseminated intravascular coagulation Diseases 0.000 claims description 7
• 239000003527 fibrinolytic agent Substances 0.000 claims description 7
• 230000003387 muscular Effects 0.000 claims description 7
• 206010040070 Septic Shock Diseases 0.000 claims description 6
• 208000026106 cerebrovascular disease Diseases 0.000 claims description 6
• 230000003511 endothelial effect Effects 0.000 claims description 6
• 230000009368 gene silencing by RNA Effects 0.000 claims description 6
• 210000005003 heart tissue Anatomy 0.000 claims description 6
• 238000002513 implantation Methods 0.000 claims description 6
• 150000003384 small molecules Chemical class 0.000 claims description 6
• 229960000103 thrombolytic agent Drugs 0.000 claims description 6
• 206010019280 Heart failures Diseases 0.000 claims description 5
• 108091030071 RNAI Proteins 0.000 claims description 5
• 208000007536 Thrombosis Diseases 0.000 claims description 5
• 239000003146 anticoagulant agent Substances 0.000 claims description 5
• 229940127219 anticoagulant drug Drugs 0.000 claims description 5
• 230000010016 myocardial function Effects 0.000 claims description 5
• 230000035755 proliferation Effects 0.000 claims description 5
• 230000036303 septic shock Effects 0.000 claims description 5
• RYYWUUFWQRZTIU-UHFFFAOYSA-K thiophosphate Chemical compound [O-]P([O-])([O-])=S RYYWUUFWQRZTIU-UHFFFAOYSA-K 0.000 claims description 5
• MJKVTPMWOKAVMS-UHFFFAOYSA-N 3-hydroxy-1-benzopyran-2-one Chemical compound C1=CC=C2OC(=O)C(O)=CC2=C1 MJKVTPMWOKAVMS-UHFFFAOYSA-N 0.000 claims description 4
• 206010002383 Angina Pectoris Diseases 0.000 claims description 4
• 206010007559 Cardiac failure congestive Diseases 0.000 claims description 4
• 206010051055 Deep vein thrombosis Diseases 0.000 claims description 4
• 206010018364 Glomerulonephritis Diseases 0.000 claims description 4
• 206010018691 Granuloma Diseases 0.000 claims description 4
• 206010061218 Inflammation Diseases 0.000 claims description 4
• 206010027476 Metastases Diseases 0.000 claims description 4
• 208000010378 Pulmonary Embolism Diseases 0.000 claims description 4
• 206010047249 Venous thrombosis Diseases 0.000 claims description 4
• 201000004339 autoimmune neuropathy Diseases 0.000 claims description 4
• 210000002798 bone marrow cell Anatomy 0.000 claims description 4
• 210000004700 fetal blood Anatomy 0.000 claims description 4
• 230000004054 inflammatory process Effects 0.000 claims description 4
• 210000004072 lung Anatomy 0.000 claims description 4
• 230000009401 metastasis Effects 0.000 claims description 4
• 230000002107 myocardial effect Effects 0.000 claims description 4
• 206010039073 rheumatoid arthritis Diseases 0.000 claims description 4
• 201000001320 Atherosclerosis Diseases 0.000 claims description 3
• 108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 claims description 3
• 102000004269 Granulocyte Colony-Stimulating Factor Human genes 0.000 claims description 3
• 206010021143 Hypoxia Diseases 0.000 claims description 3
• 208000006011 Stroke Diseases 0.000 claims description 3
• 230000007954 hypoxia Effects 0.000 claims description 3
• 230000000302 ischemic effect Effects 0.000 claims description 3
• 201000000596 systemic lupus erythematosus Diseases 0.000 claims description 3
• BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 claims description 2
• 108010012236 Chemokines Proteins 0.000 claims description 2
• 102000019034 Chemokines Human genes 0.000 claims description 2
• 101150021185 FGF gene Proteins 0.000 claims description 2
• 102000004457 Granulocyte-Macrophage Colony-Stimulating Factor Human genes 0.000 claims description 2
• 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 claims description 2
• HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 claims description 2
• 108090001007 Interleukin-8 Proteins 0.000 claims description 2
• 102000004890 Interleukin-8 Human genes 0.000 claims description 2
• 102100020880 Kit ligand Human genes 0.000 claims description 2
• 101710177504 Kit ligand Proteins 0.000 claims description 2
• 108010023197 Streptokinase Proteins 0.000 claims description 2
• 102100021669 Stromal cell-derived factor 1 Human genes 0.000 claims description 2
• 101710088580 Stromal cell-derived factor 1 Proteins 0.000 claims description 2
• 108090000373 Tissue Plasminogen Activator Proteins 0.000 claims description 2
• 102000003978 Tissue Plasminogen Activator Human genes 0.000 claims description 2
• 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 claims description 2
• 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 claims description 2
• 229960001138 acetylsalicylic acid Drugs 0.000 claims description 2
• XRCFXMGQEVUZFC-UHFFFAOYSA-N anisindione Chemical compound C1=CC(OC)=CC=C1C1C(=O)C2=CC=CC=C2C1=O XRCFXMGQEVUZFC-UHFFFAOYSA-N 0.000 claims description 2
• 229960002138 anisindione Drugs 0.000 claims description 2
• 229940030225 antihemorrhagics Drugs 0.000 claims description 2
• 230000002526 effect on cardiovascular system Effects 0.000 claims description 2
• 210000001671 embryonic stem cell Anatomy 0.000 claims description 2
• 230000000025 haemostatic effect Effects 0.000 claims description 2
• 229960002897 heparin Drugs 0.000 claims description 2
• 229920000669 heparin Polymers 0.000 claims description 2
• 108010073863 saruplase Proteins 0.000 claims description 2
• 229960005202 streptokinase Drugs 0.000 claims description 2
• 229960000187 tissue plasminogen activator Drugs 0.000 claims description 2
• 229960005356 urokinase Drugs 0.000 claims description 2
• PJVWKTKQMONHTI-UHFFFAOYSA-N warfarin Chemical compound OC=1C2=CC=CC=C2OC(=O)C=1C(CC(=O)C)C1=CC=CC=C1 PJVWKTKQMONHTI-UHFFFAOYSA-N 0.000 claims description 2
• 229960005080 warfarin Drugs 0.000 claims description 2
• 108091027757 Deoxyribozyme Proteins 0.000 abstract description 18
• 238000013519 translation Methods 0.000 abstract description 16
• 108020000948 Antisense Oligonucleotides Proteins 0.000 abstract description 13
• 108090000994 Catalytic RNA Proteins 0.000 abstract description 8
• 102000053642 Catalytic RNA Human genes 0.000 abstract description 8
• 108091092562 ribozyme Proteins 0.000 abstract description 8
• 239000004480 active ingredient Substances 0.000 abstract description 5
• 229940088598 enzyme Drugs 0.000 description 74
• 241000700159 Rattus Species 0.000 description 38
• 238000003776 cleavage reaction Methods 0.000 description 36
• 108091032973 (ribonucleotides)n+m Proteins 0.000 description 34
• 230000007017 scission Effects 0.000 description 33
• 235000000346 sugar Nutrition 0.000 description 19
• 230000014616 translation Effects 0.000 description 18
• 230000000694 effects Effects 0.000 description 17
• FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 16
• 210000002966 serum Anatomy 0.000 description 15
• 102000053602 DNA Human genes 0.000 description 14
• 102000004887 Transforming Growth Factor beta Human genes 0.000 description 13
• 108090001012 Transforming Growth Factor beta Proteins 0.000 description 13
• 230000006870 function Effects 0.000 description 13
• 230000001965 increasing effect Effects 0.000 description 13
• 239000000203 mixture Substances 0.000 description 13
• 102000004169 proteins and genes Human genes 0.000 description 13
• ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 13
• 230000014621 translational initiation Effects 0.000 description 13
• 239000011780 sodium chloride Substances 0.000 description 12
• 108091081024 Start codon Proteins 0.000 description 11
• 150000001875 compounds Chemical class 0.000 description 11
• 230000009467 reduction Effects 0.000 description 11
• 239000000758 substrate Substances 0.000 description 11
• KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 10
• 241001465754 Metazoa Species 0.000 description 10
• 230000015556 catabolic process Effects 0.000 description 10
• 238000006243 chemical reaction Methods 0.000 description 10
• 238000006731 degradation reaction Methods 0.000 description 10
• 210000002889 endothelial cell Anatomy 0.000 description 10
• 238000009396 hybridization Methods 0.000 description 10
• 239000002502 liposome Substances 0.000 description 10
• 239000000047 product Substances 0.000 description 10
• LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 9
• 229920002472 Starch Polymers 0.000 description 9
• 210000001367 artery Anatomy 0.000 description 9
• 230000006378 damage Effects 0.000 description 9
• 210000000107 myocyte Anatomy 0.000 description 9
• 241000894007 species Species 0.000 description 9
• 238000001890 transfection Methods 0.000 description 9
• 238000011282 treatment Methods 0.000 description 9
• YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 8
• 108010088842 Fibrinolysin Proteins 0.000 description 8
• 108020005038 Terminator Codon Proteins 0.000 description 8
• 108010031318 Vitronectin Proteins 0.000 description 8
• 102100035140 Vitronectin Human genes 0.000 description 8
• 208000027418 Wounds and injury Diseases 0.000 description 8
• 230000001419 dependent effect Effects 0.000 description 8
• 239000000499 gel Substances 0.000 description 8
• 238000000338 in vitro Methods 0.000 description 8
• 208000014674 injury Diseases 0.000 description 8
• 239000002609 medium Substances 0.000 description 8
• 239000000546 pharmaceutical excipient Substances 0.000 description 8
• 229940012957 plasmin Drugs 0.000 description 8
• 238000002360 preparation method Methods 0.000 description 8
• 239000000243 solution Substances 0.000 description 8
• 108091035707 Consensus sequence Proteins 0.000 description 7
• 206010016654 Fibrosis Diseases 0.000 description 7
• 108091028043 Nucleic acid sequence Proteins 0.000 description 7
• 101000609257 Rattus norvegicus Plasminogen activator inhibitor 1 Proteins 0.000 description 7
• 150000001413 amino acids Chemical group 0.000 description 7
• 210000000648 angioblast Anatomy 0.000 description 7
• 230000015572 biosynthetic process Effects 0.000 description 7
• LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 7
• 210000004024 hepatic stellate cell Anatomy 0.000 description 7
• 239000001257 hydrogen Substances 0.000 description 7
• 229910052739 hydrogen Inorganic materials 0.000 description 7
• 230000006698 induction Effects 0.000 description 7
• 239000007925 intracardiac injection Substances 0.000 description 7
• 210000002540 macrophage Anatomy 0.000 description 7
• 239000002953 phosphate buffered saline Substances 0.000 description 7
• 230000002441 reversible effect Effects 0.000 description 7
• 150000003839 salts Chemical class 0.000 description 7
• 235000019698 starch Nutrition 0.000 description 7
• 239000000126 substance Substances 0.000 description 7
• 150000008163 sugars Chemical class 0.000 description 7
• 239000000725 suspension Substances 0.000 description 7
• 230000001225 therapeutic effect Effects 0.000 description 7
• WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 6
• DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
• JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 6
• 239000002775 capsule Substances 0.000 description 6
• 210000001715 carotid artery Anatomy 0.000 description 6
• 230000004761 fibrosis Effects 0.000 description 6
• 238000009472 formulation Methods 0.000 description 6
• 239000000463 material Substances 0.000 description 6
• 238000005259 measurement Methods 0.000 description 6
• 239000012188 paraffin wax Substances 0.000 description 6
• 229920001223 polyethylene glycol Polymers 0.000 description 6
• 229960000856 protein c Drugs 0.000 description 6
• 238000010186 staining Methods 0.000 description 6
• 239000008107 starch Substances 0.000 description 6
• RWQNBRDOKXIBIV-UHFFFAOYSA-N thymine Chemical compound CC1=CNC(=O)NC1=O RWQNBRDOKXIBIV-UHFFFAOYSA-N 0.000 description 6
• 238000013518 transcription Methods 0.000 description 6
• 230000035897 transcription Effects 0.000 description 6
• PQSUYGKTWSAVDQ-ZVIOFETBSA-N Aldosterone Chemical compound C([C@@]1([C@@H](C(=O)CO)CC[C@H]1[C@@H]1CC2)C=O)[C@H](O)[C@@H]1[C@]1(C)C2=CC(=O)CC1 PQSUYGKTWSAVDQ-ZVIOFETBSA-N 0.000 description 5
• PQSUYGKTWSAVDQ-UHFFFAOYSA-N Aldosterone Natural products C1CC2C3CCC(C(=O)CO)C3(C=O)CC(O)C2C2(C)C1=CC(=O)CC2 PQSUYGKTWSAVDQ-UHFFFAOYSA-N 0.000 description 5
• 101800004937 Protein C Proteins 0.000 description 5
• 102000017975 Protein C Human genes 0.000 description 5
• 101800001700 Saposin-D Proteins 0.000 description 5
• 241000251131 Sphyrna Species 0.000 description 5
• 229960002478 aldosterone Drugs 0.000 description 5
• 230000001640 apoptogenic effect Effects 0.000 description 5
• 239000011616 biotin Substances 0.000 description 5
• 229960002685 biotin Drugs 0.000 description 5
• 230000007246 mechanism Effects 0.000 description 5
• 230000001404 mediated effect Effects 0.000 description 5
• 230000000750 progressive effect Effects 0.000 description 5
• 238000003757 reverse transcription PCR Methods 0.000 description 5
• 208000035657 Abasia Diseases 0.000 description 4
• 102000002260 Alkaline Phosphatase Human genes 0.000 description 4
• 108020004774 Alkaline Phosphatase Proteins 0.000 description 4
• 108020004705 Codon Proteins 0.000 description 4
• 102100036912 Desmin Human genes 0.000 description 4
• 108010044052 Desmin Proteins 0.000 description 4
• 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 4
• 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 4
• ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 4
• 108010010803 Gelatin Proteins 0.000 description 4
• PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 4
• 206010067125 Liver injury Diseases 0.000 description 4
• 108700026244 Open Reading Frames Proteins 0.000 description 4
• 102000013566 Plasminogen Human genes 0.000 description 4
• 108010051456 Plasminogen Proteins 0.000 description 4
• 102000010752 Plasminogen Inactivators Human genes 0.000 description 4
• 108091036066 Three prime untranslated region Proteins 0.000 description 4
• IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 4
• 230000004913 activation Effects 0.000 description 4
• 235000020958 biotin Nutrition 0.000 description 4
• 210000001185 bone marrow Anatomy 0.000 description 4
• 238000004113 cell culture Methods 0.000 description 4
• 230000001413 cellular effect Effects 0.000 description 4
• 239000002299 complementary DNA Substances 0.000 description 4
• OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical compound NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 description 4
• 210000005045 desmin Anatomy 0.000 description 4
• 238000010790 dilution Methods 0.000 description 4
• 239000012895 dilution Substances 0.000 description 4
• MWRBNPKJOOWZPW-CLFAGFIQSA-N dioleoyl phosphatidylethanolamine Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC(COP(O)(=O)OCCN)OC(=O)CCCCCCC\C=C/CCCCCCCC MWRBNPKJOOWZPW-CLFAGFIQSA-N 0.000 description 4
• 210000002744 extracellular matrix Anatomy 0.000 description 4
• 230000003352 fibrogenic effect Effects 0.000 description 4
• 229920000159 gelatin Polymers 0.000 description 4
• 239000008273 gelatin Substances 0.000 description 4
• 235000019322 gelatine Nutrition 0.000 description 4
• 235000011852 gelatine desserts Nutrition 0.000 description 4
• UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical compound O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 description 4
• 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 4
• 238000001727 in vivo Methods 0.000 description 4
• 210000003734 kidney Anatomy 0.000 description 4
• HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
• 239000000825 pharmaceutical preparation Substances 0.000 description 4
• 239000002797 plasminogen activator inhibitor Substances 0.000 description 4
• 201000002793 renal fibrosis Diseases 0.000 description 4
• 239000003826 tablet Substances 0.000 description 4
• 239000000454 talc Substances 0.000 description 4
• 229910052623 talc Inorganic materials 0.000 description 4
• 235000012222 talc Nutrition 0.000 description 4
• 230000008685 targeting Effects 0.000 description 4
• 238000001262 western blot Methods 0.000 description 4
• 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 3
• QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
• CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
• 102000005862 Angiotensin II Human genes 0.000 description 3
• 101800000733 Angiotensin-2 Proteins 0.000 description 3
• 108091026890 Coding region Proteins 0.000 description 3
• FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 3
• 102100031573 Hematopoietic progenitor cell antigen CD34 Human genes 0.000 description 3
• 101000777663 Homo sapiens Hematopoietic progenitor cell antigen CD34 Proteins 0.000 description 3
• 201000009794 Idiopathic Pulmonary Fibrosis Diseases 0.000 description 3
• CZGUSIXMZVURDU-JZXHSEFVSA-N Ile(5)-angiotensin II Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC=1C=CC=CC=1)C([O-])=O)NC(=O)[C@@H](NC(=O)[C@H](CCCNC(N)=[NH2+])NC(=O)[C@@H]([NH3+])CC([O-])=O)C(C)C)C1=CC=C(O)C=C1 CZGUSIXMZVURDU-JZXHSEFVSA-N 0.000 description 3
• GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
• 108091026898 Leader sequence (mRNA) Proteins 0.000 description 3
• 102000002274 Matrix Metalloproteinases Human genes 0.000 description 3
• 108010000684 Matrix Metalloproteinases Proteins 0.000 description 3
• 241000699666 Mus <mouse, genus> Species 0.000 description 3
• 101710163270 Nuclease Proteins 0.000 description 3
• 102000001938 Plasminogen Activators Human genes 0.000 description 3
• 108010001014 Plasminogen Activators Proteins 0.000 description 3
• 108010077971 Plasminogen Inactivators Proteins 0.000 description 3
• 239000002202 Polyethylene glycol Substances 0.000 description 3
• CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 3
• 229930006000 Sucrose Natural products 0.000 description 3
• CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 3
• 230000033115 angiogenesis Effects 0.000 description 3
• 229950006323 angiotensin ii Drugs 0.000 description 3
• 239000011230 binding agent Substances 0.000 description 3
• 239000000872 buffer Substances 0.000 description 3
• 239000001506 calcium phosphate Substances 0.000 description 3
• 150000001720 carbohydrates Chemical class 0.000 description 3
• 235000014633 carbohydrates Nutrition 0.000 description 3
• 210000001168 carotid artery common Anatomy 0.000 description 3
• 239000003153 chemical reaction reagent Substances 0.000 description 3
• HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol group Chemical group [C@@H]1(CC[C@H]2[C@@H]3CC=C4C[C@@H](O)CC[C@]4(C)[C@H]3CC[C@]12C)[C@H](C)CCCC(C)C HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 3
• 238000000576 coating method Methods 0.000 description 3
• 235000014113 dietary fatty acids Nutrition 0.000 description 3
• 239000008298 dragée Substances 0.000 description 3
• 238000001962 electrophoresis Methods 0.000 description 3
• 239000003623 enhancer Substances 0.000 description 3
• 230000002255 enzymatic effect Effects 0.000 description 3
• 238000002474 experimental method Methods 0.000 description 3
• 229960000301 factor viii Drugs 0.000 description 3
• 239000000194 fatty acid Substances 0.000 description 3
• 229930195729 fatty acid Natural products 0.000 description 3
• GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 3
• 239000012634 fragment Substances 0.000 description 3
• 210000005260 human cell Anatomy 0.000 description 3
• 229930195733 hydrocarbon Natural products 0.000 description 3
• 150000002430 hydrocarbons Chemical class 0.000 description 3
• 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 3
• 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 3
• UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 3
• 238000011534 incubation Methods 0.000 description 3
• 208000036971 interstitial lung disease 2 Diseases 0.000 description 3
• 238000007912 intraperitoneal administration Methods 0.000 description 3
• 238000002372 labelling Methods 0.000 description 3
• 239000008101 lactose Substances 0.000 description 3
• 150000002632 lipids Chemical class 0.000 description 3
• 239000007788 liquid Substances 0.000 description 3
• 210000004185 liver Anatomy 0.000 description 3
• 230000005012 migration Effects 0.000 description 3
• 238000013508 migration Methods 0.000 description 3
• 230000033885 plasminogen activation Effects 0.000 description 3
• 229940127126 plasminogen activator Drugs 0.000 description 3
• 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 3
• 239000001267 polyvinylpyrrolidone Substances 0.000 description 3
• 229920000036 polyvinylpyrrolidone Polymers 0.000 description 3
• 230000008569 process Effects 0.000 description 3
• 201000001474 proteinuria Diseases 0.000 description 3
• 230000004044 response Effects 0.000 description 3
• 238000010839 reverse transcription Methods 0.000 description 3
• 229920002477 rna polymer Polymers 0.000 description 3
• 239000002904 solvent Substances 0.000 description 3
• 239000000600 sorbitol Substances 0.000 description 3
• 239000003381 stabilizer Substances 0.000 description 3
• 239000005720 sucrose Substances 0.000 description 3
• 239000000829 suppository Substances 0.000 description 3
• XXYIANZGUOSQHY-XLPZGREQSA-N thymidine 3'-monophosphate Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](OP(O)(O)=O)C1 XXYIANZGUOSQHY-XLPZGREQSA-N 0.000 description 3
• 229940113082 thymine Drugs 0.000 description 3
• 230000005945 translocation Effects 0.000 description 3
• 150000003626 triacylglycerols Chemical class 0.000 description 3
• 230000002861 ventricular Effects 0.000 description 3
• UUUHXMGGBIUAPW-UHFFFAOYSA-N 1-[1-[2-[[5-amino-2-[[1-[5-(diaminomethylideneamino)-2-[[1-[3-(1h-indol-3-yl)-2-[(5-oxopyrrolidine-2-carbonyl)amino]propanoyl]pyrrolidine-2-carbonyl]amino]pentanoyl]pyrrolidine-2-carbonyl]amino]-5-oxopentanoyl]amino]-3-methylpentanoyl]pyrrolidine-2-carbon Chemical compound C1CCC(C(=O)N2C(CCC2)C(O)=O)N1C(=O)C(C(C)CC)NC(=O)C(CCC(N)=O)NC(=O)C1CCCN1C(=O)C(CCCN=C(N)N)NC(=O)C1CCCN1C(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)C1CCC(=O)N1 UUUHXMGGBIUAPW-UHFFFAOYSA-N 0.000 description 2
• KSXTUUUQYQYKCR-LQDDAWAPSA-M 2,3-bis[[(z)-octadec-9-enoyl]oxy]propyl-trimethylazanium;chloride Chemical compound [Cl-].CCCCCCCC\C=C/CCCCCCCC(=O)OCC(C[N+](C)(C)C)OC(=O)CCCCCCC\C=C/CCCCCCCC KSXTUUUQYQYKCR-LQDDAWAPSA-M 0.000 description 2
• QRXMUCSWCMTJGU-UHFFFAOYSA-N 5-bromo-4-chloro-3-indolyl phosphate Chemical compound C1=C(Br)C(Cl)=C2C(OP(O)(=O)O)=CNC2=C1 QRXMUCSWCMTJGU-UHFFFAOYSA-N 0.000 description 2
• 229930024421 Adenine Natural products 0.000 description 2
• GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 2
• 108090001008 Avidin Proteins 0.000 description 2
• DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 2
• 241000283707 Capra Species 0.000 description 2
• HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
• FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 2
• HMFHBZSHGGEWLO-SOOFDHNKSA-N D-ribofuranose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H]1O HMFHBZSHGGEWLO-SOOFDHNKSA-N 0.000 description 2
• 102100033215 DNA nucleotidylexotransferase Human genes 0.000 description 2
• 230000006820 DNA synthesis Effects 0.000 description 2
• KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
• LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 2
• 108060002716 Exonuclease Proteins 0.000 description 2
• 108010054218 Factor VIII Proteins 0.000 description 2
• 102000001690 Factor VIII Human genes 0.000 description 2
• WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
• WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 2
• 101001066129 Homo sapiens Glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 2
• 229930010555 Inosine Natural products 0.000 description 2
• UGQMRVRMYYASKQ-KQYNXXCUSA-N Inosine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C2=NC=NC(O)=C2N=C1 UGQMRVRMYYASKQ-KQYNXXCUSA-N 0.000 description 2
• 108010047852 Integrin alphaVbeta3 Proteins 0.000 description 2
• 102000004270 Peptidyl-Dipeptidase A Human genes 0.000 description 2
• 108090000882 Peptidyl-Dipeptidase A Proteins 0.000 description 2
• ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
• 108010021757 Polynucleotide 5'-Hydroxyl-Kinase Proteins 0.000 description 2
• 102000008422 Polynucleotide 5'-hydroxyl-kinase Human genes 0.000 description 2
• PYMYPHUHKUWMLA-LMVFSUKVSA-N Ribose Natural products OC[C@@H](O)[C@@H](O)[C@@H](O)C=O PYMYPHUHKUWMLA-LMVFSUKVSA-N 0.000 description 2
• 206010040047 Sepsis Diseases 0.000 description 2
• VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
• GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 2
• 108700009124 Transcription Initiation Site Proteins 0.000 description 2
• 239000007983 Tris buffer Substances 0.000 description 2
• ISAKRJDGNUQOIC-UHFFFAOYSA-N Uracil Chemical compound O=C1C=CNC(=O)N1 ISAKRJDGNUQOIC-UHFFFAOYSA-N 0.000 description 2
• 230000001594 aberrant effect Effects 0.000 description 2
• 238000010521 absorption reaction Methods 0.000 description 2
• 230000009471 action Effects 0.000 description 2
• 230000001154 acute effect Effects 0.000 description 2
• 238000007792 addition Methods 0.000 description 2
• 229960000643 adenine Drugs 0.000 description 2
• 125000000217 alkyl group Chemical group 0.000 description 2
• HMFHBZSHGGEWLO-UHFFFAOYSA-N alpha-D-Furanose-Ribose Natural products OCC1OC(O)C(O)C1O HMFHBZSHGGEWLO-UHFFFAOYSA-N 0.000 description 2
• WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 description 2
• 238000004458 analytical method Methods 0.000 description 2
• 230000000692 anti-sense effect Effects 0.000 description 2
• 238000013459 approach Methods 0.000 description 2
• 239000007864 aqueous solution Substances 0.000 description 2
• 239000012298 atmosphere Substances 0.000 description 2
• 238000000376 autoradiography Methods 0.000 description 2
• WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
• IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 2
• 230000000903 blocking effect Effects 0.000 description 2
• 210000004369 blood Anatomy 0.000 description 2
• 239000008280 blood Substances 0.000 description 2
• CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical class [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 2
• 239000001768 carboxy methyl cellulose Substances 0.000 description 2
• 239000000969 carrier Substances 0.000 description 2
• 108020001778 catalytic domains Proteins 0.000 description 2
• 239000013592 cell lysate Substances 0.000 description 2
• 239000001913 cellulose Substances 0.000 description 2
• 229920002678 cellulose Polymers 0.000 description 2
• 230000008859 change Effects 0.000 description 2
• 208000019425 cirrhosis of liver Diseases 0.000 description 2
• 230000015271 coagulation Effects 0.000 description 2
• 238000005345 coagulation Methods 0.000 description 2
• 239000003636 conditioned culture medium Substances 0.000 description 2
• 239000000562 conjugate Substances 0.000 description 2
• 239000006071 cream Substances 0.000 description 2
• 229940104302 cytosine Drugs 0.000 description 2
• 230000001086 cytosolic effect Effects 0.000 description 2
• 230000007423 decrease Effects 0.000 description 2
• 238000010217 densitometric analysis Methods 0.000 description 2
• 238000011161 development Methods 0.000 description 2
• 230000018109 developmental process Effects 0.000 description 2
• 238000009826 distribution Methods 0.000 description 2
• AUZONCFQVSMFAP-UHFFFAOYSA-N disulfiram Chemical compound CCN(CC)C(=S)SSC(=S)N(CC)CC AUZONCFQVSMFAP-UHFFFAOYSA-N 0.000 description 2
• 231100000673 dose–response relationship Toxicity 0.000 description 2
• 230000009977 dual effect Effects 0.000 description 2
• 239000000975 dye Substances 0.000 description 2
• 210000003038 endothelium Anatomy 0.000 description 2
• 238000005516 engineering process Methods 0.000 description 2
• 102000013165 exonuclease Human genes 0.000 description 2
• 239000010685 fatty oil Substances 0.000 description 2
• 230000020764 fibrinolysis Effects 0.000 description 2
• 229930182830 galactose Natural products 0.000 description 2
• 210000004051 gastric juice Anatomy 0.000 description 2
• 206010061989 glomerulosclerosis Diseases 0.000 description 2
• 239000008103 glucose Substances 0.000 description 2
• 230000036541 health Effects 0.000 description 2
• 231100000753 hepatic injury Toxicity 0.000 description 2
• 102000047486 human GAPDH Human genes 0.000 description 2
• 229920001477 hydrophilic polymer Polymers 0.000 description 2
• 230000002209 hydrophobic effect Effects 0.000 description 2
• FDGQSTZJBFJUBT-UHFFFAOYSA-N hypoxanthine Chemical compound O=C1NC=NC2=C1NC=N2 FDGQSTZJBFJUBT-UHFFFAOYSA-N 0.000 description 2
• 230000000642 iatrogenic effect Effects 0.000 description 2
• 229960003786 inosine Drugs 0.000 description 2
• 230000003993 interaction Effects 0.000 description 2
• 238000001990 intravenous administration Methods 0.000 description 2
• 125000005647 linker group Chemical group 0.000 description 2
• 239000000314 lubricant Substances 0.000 description 2
• 235000019359 magnesium stearate Nutrition 0.000 description 2
• 239000011159 matrix material Substances 0.000 description 2
• 230000008018 melting Effects 0.000 description 2
• 238000002844 melting Methods 0.000 description 2
• 239000012528 membrane Substances 0.000 description 2
• 210000004379 membrane Anatomy 0.000 description 2
• 210000004165 myocardium Anatomy 0.000 description 2
• 239000013642 negative control Substances 0.000 description 2
• 201000009925 nephrosclerosis Diseases 0.000 description 2
• 230000001293 nucleolytic effect Effects 0.000 description 2
• XNGIFLGASWRNHJ-UHFFFAOYSA-L phthalate(2-) Chemical compound [O-]C(=O)C1=CC=CC=C1C([O-])=O XNGIFLGASWRNHJ-UHFFFAOYSA-L 0.000 description 2
• 229920001606 poly(lactic acid-co-glycolic acid) Polymers 0.000 description 2
• 229920002401 polyacrylamide Polymers 0.000 description 2
• 229920000768 polyamine Polymers 0.000 description 2
• 229920000728 polyester Polymers 0.000 description 2
• 229920000642 polymer Polymers 0.000 description 2
• 102000054765 polymorphisms of proteins Human genes 0.000 description 2
• 102000040430 polynucleotide Human genes 0.000 description 2
• 108091033319 polynucleotide Proteins 0.000 description 2
• 239000002157 polynucleotide Substances 0.000 description 2
• 230000003389 potentiating effect Effects 0.000 description 2
• 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 2
• 238000011552 rat model Methods 0.000 description 2
• 239000011541 reaction mixture Substances 0.000 description 2
• 230000035484 reaction time Effects 0.000 description 2
• 239000003642 reactive oxygen metabolite Substances 0.000 description 2
• 108020003175 receptors Proteins 0.000 description 2
• 102000005962 receptors Human genes 0.000 description 2
• 230000036454 renin-angiotensin system Effects 0.000 description 2
• 230000003362 replicative effect Effects 0.000 description 2
• 238000011160 research Methods 0.000 description 2
• 238000004007 reversed phase HPLC Methods 0.000 description 2
• PFNFFQXMRSDOHW-UHFFFAOYSA-N spermine Chemical compound NCCCNCCCCNCCCN PFNFFQXMRSDOHW-UHFFFAOYSA-N 0.000 description 2
• 238000011630 spontaneously hypertensive stroke prone rat Methods 0.000 description 2
• 238000012453 sprague-dawley rat model Methods 0.000 description 2
• 230000000638 stimulation Effects 0.000 description 2
• UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
• 125000001424 substituent group Chemical group 0.000 description 2
• 238000006467 substitution reaction Methods 0.000 description 2
• 239000002511 suppository base Substances 0.000 description 2
• 238000001356 surgical procedure Methods 0.000 description 2
• 238000003786 synthesis reaction Methods 0.000 description 2
• 238000012360 testing method Methods 0.000 description 2
• 238000002560 therapeutic procedure Methods 0.000 description 2
• 229940104230 thymidine Drugs 0.000 description 2
• 230000036962 time dependent Effects 0.000 description 2
• QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical class [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 2
• LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 2
• 239000003981 vehicle Substances 0.000 description 2
• KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 1
• LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 1
• BHQCQFFYRZLCQQ-UHFFFAOYSA-N (3alpha,5alpha,7alpha,12alpha)-3,7,12-trihydroxy-cholan-24-oic acid Natural products OC1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)C(O)C2 BHQCQFFYRZLCQQ-UHFFFAOYSA-N 0.000 description 1
• PORPENFLTBBHSG-MGBGTMOVSA-N 1,2-dihexadecanoyl-sn-glycerol-3-phosphate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(O)=O)OC(=O)CCCCCCCCCCCCCCC PORPENFLTBBHSG-MGBGTMOVSA-N 0.000 description 1
• QAPSNMNOIOSXSQ-YNEHKIRRSA-N 1-[(2r,4s,5r)-4-[tert-butyl(dimethyl)silyl]oxy-5-(hydroxymethyl)oxolan-2-yl]-5-methylpyrimidine-2,4-dione Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O[Si](C)(C)C(C)(C)C)C1 QAPSNMNOIOSXSQ-YNEHKIRRSA-N 0.000 description 1
• IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
• IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
• VGONTNSXDCQUGY-RRKCRQDMSA-N 2'-deoxyinosine Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(N=CNC2=O)=C2N=C1 VGONTNSXDCQUGY-RRKCRQDMSA-N 0.000 description 1
• WJBNIBFTNGZFBW-DJLDLDEBSA-N 2'-deoxynebularine Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C2=NC=NC=C2N=C1 WJBNIBFTNGZFBW-DJLDLDEBSA-N 0.000 description 1
• HDZZVAMISRMYHH-UHFFFAOYSA-N 2-(4-aminopyrrolo[2,3-d]pyrimidin-7-yl)-5-(hydroxymethyl)oxolane-3,4-diol Chemical compound C1=CC=2C(N)=NC=NC=2N1C1OC(CO)C(O)C1O HDZZVAMISRMYHH-UHFFFAOYSA-N 0.000 description 1
• JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
• QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
• JRYMOPZHXMVHTA-DAGMQNCNSA-N 2-amino-7-[(2r,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-1h-pyrrolo[2,3-d]pyrimidin-4-one Chemical compound C1=CC=2C(=O)NC(N)=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O JRYMOPZHXMVHTA-DAGMQNCNSA-N 0.000 description 1
• HZLCGUXUOFWCCN-UHFFFAOYSA-N 2-hydroxynonadecane-1,2,3-tricarboxylic acid Chemical compound CCCCCCCCCCCCCCCCC(C(O)=O)C(O)(C(O)=O)CC(O)=O HZLCGUXUOFWCCN-UHFFFAOYSA-N 0.000 description 1
• 108020005345 3' Untranslated Regions Proteins 0.000 description 1
• 108020003589 5' Untranslated Regions Proteins 0.000 description 1
• VKKXEIQIGGPMHT-UHFFFAOYSA-N 7h-purine-2,8-diamine Chemical class NC1=NC=C2NC(N)=NC2=N1 VKKXEIQIGGPMHT-UHFFFAOYSA-N 0.000 description 1
• CZVCGJBESNRLEQ-UHFFFAOYSA-N 7h-purine;pyrimidine Chemical compound C1=CN=CN=C1.C1=NC=C2NC=NC2=N1 CZVCGJBESNRLEQ-UHFFFAOYSA-N 0.000 description 1
• NQAZHXBSLFDVKM-KVQBGUIXSA-N 9-[(2r,4s,5r)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-3h-purine-2,6-dione Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(NC(=O)NC2=O)=C2N=C1 NQAZHXBSLFDVKM-KVQBGUIXSA-N 0.000 description 1
• 244000215068 Acacia senegal Species 0.000 description 1
• 208000007788 Acute Liver Failure Diseases 0.000 description 1
• 206010000804 Acute hepatic failure Diseases 0.000 description 1
• 229920001817 Agar Polymers 0.000 description 1
• GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
• VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
• 206010002091 Anaesthesia Diseases 0.000 description 1
• 102000008873 Angiotensin II receptor Human genes 0.000 description 1
• 108050000824 Angiotensin II receptor Proteins 0.000 description 1
• 241000416162 Astragalus gummifer Species 0.000 description 1
• 102000004506 Blood Proteins Human genes 0.000 description 1
• 108010017384 Blood Proteins Proteins 0.000 description 1
• 239000004215 Carbon black (E152) Substances 0.000 description 1
• 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
• 206010007558 Cardiac failure chronic Diseases 0.000 description 1
• 206010007572 Cardiac hypertrophy Diseases 0.000 description 1
• 208000006029 Cardiomegaly Diseases 0.000 description 1
• 208000031229 Cardiomyopathies Diseases 0.000 description 1
• 208000010867 Carotid Artery injury Diseases 0.000 description 1
• 208000002177 Cataract Diseases 0.000 description 1
• 241000700199 Cavia porcellus Species 0.000 description 1
• 239000004380 Cholic acid Substances 0.000 description 1
• 102100036213 Collagen alpha-2(I) chain Human genes 0.000 description 1
• 229920002261 Corn starch Polymers 0.000 description 1
• 239000004971 Cross linker Substances 0.000 description 1
• 102000004127 Cytokines Human genes 0.000 description 1
• 108090000695 Cytokines Proteins 0.000 description 1
• FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
• 108010008286 DNA nucleotidylexotransferase Proteins 0.000 description 1
• XULFJDKZVHTRLG-JDVCJPALSA-N DOSPA trifluoroacetate Chemical compound [O-]C(=O)C(F)(F)F.CCCCCCCC\C=C/CCCCCCCCOCC(C[N+](C)(C)CCNC(=O)C(CCCNCCCN)NCCCN)OCCCCCCCC\C=C/CCCCCCCC XULFJDKZVHTRLG-JDVCJPALSA-N 0.000 description 1
• AHCYMLUZIRLXAA-SHYZEUOFSA-N Deoxyuridine 5'-triphosphate Chemical compound O1[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)C[C@@H]1N1C(=O)NC(=O)C=C1 AHCYMLUZIRLXAA-SHYZEUOFSA-N 0.000 description 1
• 229920002307 Dextran Polymers 0.000 description 1
• 208000007342 Diabetic Nephropathies Diseases 0.000 description 1
• 235000019739 Dicalciumphosphate Nutrition 0.000 description 1
• LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
• 102000004533 Endonucleases Human genes 0.000 description 1
• 108010042407 Endonucleases Proteins 0.000 description 1
• 108010067770 Endopeptidase K Proteins 0.000 description 1
• 241000206602 Eukaryota Species 0.000 description 1
• 206010018367 Glomerulonephritis chronic Diseases 0.000 description 1
• 108091027874 Group I catalytic intron Proteins 0.000 description 1
• 229920000084 Gum arabic Polymers 0.000 description 1
• 239000007995 HEPES buffer Substances 0.000 description 1
• 108090001102 Hammerhead ribozyme Proteins 0.000 description 1
• 208000000435 Heart Rupture Diseases 0.000 description 1
• 206010019668 Hepatic fibrosis Diseases 0.000 description 1
• 241000724709 Hepatitis delta virus Species 0.000 description 1
• 206010019799 Hepatitis viral Diseases 0.000 description 1
• 241000282412 Homo Species 0.000 description 1
• 101000875067 Homo sapiens Collagen alpha-2(I) chain Proteins 0.000 description 1
• 101000934372 Homo sapiens Macrosialin Proteins 0.000 description 1
• 101000605403 Homo sapiens Plasminogen Proteins 0.000 description 1
• 108010001336 Horseradish Peroxidase Proteins 0.000 description 1
• UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
• UGQMRVRMYYASKQ-UHFFFAOYSA-N Hypoxanthine nucleoside Natural products OC1C(O)C(CO)OC1N1C(NC=NC2=O)=C2N=C1 UGQMRVRMYYASKQ-UHFFFAOYSA-N 0.000 description 1
• 108020005350 Initiator Codon Proteins 0.000 description 1
• YQEZLKZALYSWHR-UHFFFAOYSA-N Ketamine Chemical compound C=1C=CC=C(Cl)C=1C1(NC)CCCCC1=O YQEZLKZALYSWHR-UHFFFAOYSA-N 0.000 description 1
• FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
• 102000000853 LDL receptors Human genes 0.000 description 1
• 108010001831 LDL receptors Proteins 0.000 description 1
• 102000043129 MHC class I family Human genes 0.000 description 1
• 108091054437 MHC class I family Proteins 0.000 description 1
• 102100025136 Macrosialin Human genes 0.000 description 1
• 235000019759 Maize starch Nutrition 0.000 description 1
• 229930195725 Mannitol Natural products 0.000 description 1
• NPPQSCRMBWNHMW-UHFFFAOYSA-N Meprobamate Chemical compound NC(=O)OCC(C)(CCC)COC(N)=O NPPQSCRMBWNHMW-UHFFFAOYSA-N 0.000 description 1
• 102000005741 Metalloproteases Human genes 0.000 description 1
• 108010006035 Metalloproteases Proteins 0.000 description 1
• 208000034486 Multi-organ failure Diseases 0.000 description 1
• 208000010718 Multiple Organ Failure Diseases 0.000 description 1
• 101100444898 Mus musculus Egr1 gene Proteins 0.000 description 1
• 206010028851 Necrosis Diseases 0.000 description 1
• 208000013901 Nephropathies and tubular disease Diseases 0.000 description 1
• 241000221960 Neurospora Species 0.000 description 1
• 101001068640 Nicotiana tabacum Basic form of pathogenesis-related protein 1 Proteins 0.000 description 1
• 108091093105 Nuclear DNA Proteins 0.000 description 1
• 108091007494 Nucleic acid- binding domains Proteins 0.000 description 1
• CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 1
• REYJJPSVUYRZGE-UHFFFAOYSA-N Octadecylamine Chemical compound CCCCCCCCCCCCCCCCCCN REYJJPSVUYRZGE-UHFFFAOYSA-N 0.000 description 1
• 241000283973 Oryctolagus cuniculus Species 0.000 description 1
• 229910019142 PO4 Inorganic materials 0.000 description 1
• 101150071746 Pbsn gene Proteins 0.000 description 1
• 229930182555 Penicillin Natural products 0.000 description 1
• JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
• 108091005804 Peptidases Proteins 0.000 description 1
• 102000035195 Peptidases Human genes 0.000 description 1
• 102000003992 Peroxidases Human genes 0.000 description 1
• ABLZXFCXXLZCGV-UHFFFAOYSA-N Phosphorous acid Chemical class OP(O)=O ABLZXFCXXLZCGV-UHFFFAOYSA-N 0.000 description 1
• 108091000080 Phosphotransferase Proteins 0.000 description 1
• 108010010336 Platelet Membrane Glycoproteins Proteins 0.000 description 1
• 102000015795 Platelet Membrane Glycoproteins Human genes 0.000 description 1
• 102100024616 Platelet endothelial cell adhesion molecule Human genes 0.000 description 1
• 102100023715 Poly(A)-specific ribonuclease PARN Human genes 0.000 description 1
• 239000004952 Polyamide Substances 0.000 description 1
• 229920000148 Polycarbophil calcium Polymers 0.000 description 1
• 239000004698 Polyethylene Substances 0.000 description 1
• 108010039918 Polylysine Proteins 0.000 description 1
• 239000004721 Polyphenylene oxide Substances 0.000 description 1
• 229920001213 Polysorbate 20 Polymers 0.000 description 1
• 241000288906 Primates Species 0.000 description 1
• 108010050808 Procollagen Proteins 0.000 description 1
• WDVSHHCDHLJJJR-UHFFFAOYSA-N Proflavine Chemical compound C1=CC(N)=CC2=NC3=CC(N)=CC=C3C=C21 WDVSHHCDHLJJJR-UHFFFAOYSA-N 0.000 description 1
• 238000012228 RNA interference-mediated gene silencing Methods 0.000 description 1
• 230000007022 RNA scission Effects 0.000 description 1
• 208000001647 Renal Insufficiency Diseases 0.000 description 1
• 206010039710 Scleroderma Diseases 0.000 description 1
• 108010022999 Serine Proteases Proteins 0.000 description 1
• 102000012479 Serine Proteases Human genes 0.000 description 1
• 235000021355 Stearic acid Nutrition 0.000 description 1
• QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
• 108010006785 Taq Polymerase Proteins 0.000 description 1
• RYYWUUFWQRZTIU-UHFFFAOYSA-N Thiophosphoric acid Chemical group OP(O)(S)=O RYYWUUFWQRZTIU-UHFFFAOYSA-N 0.000 description 1
• 206010044248 Toxic shock syndrome Diseases 0.000 description 1
• 231100000650 Toxic shock syndrome Toxicity 0.000 description 1
• 229920001615 Tragacanth Polymers 0.000 description 1
• 102000004357 Transferases Human genes 0.000 description 1
• 108090000992 Transferases Proteins 0.000 description 1
• 239000013504 Triton X-100 Substances 0.000 description 1
• 229920004890 Triton X-100 Polymers 0.000 description 1
• 108091023045 Untranslated Region Proteins 0.000 description 1
• 208000004608 Ureteral Obstruction Diseases 0.000 description 1
• 206010046406 Ureteric obstruction Diseases 0.000 description 1
• 102100031358 Urokinase-type plasminogen activator Human genes 0.000 description 1
• SMEGJBVQLJJKKX-HOTMZDKISA-N [(2R,3S,4S,5R,6R)-5-acetyloxy-3,4,6-trihydroxyoxan-2-yl]methyl acetate Chemical compound CC(=O)OC[C@@H]1[C@H]([C@@H]([C@H]([C@@H](O1)O)OC(=O)C)O)O SMEGJBVQLJJKKX-HOTMZDKISA-N 0.000 description 1
• 230000005856 abnormality Effects 0.000 description 1
• 238000002835 absorbance Methods 0.000 description 1
• 235000010489 acacia gum Nutrition 0.000 description 1
• 239000000205 acacia gum Substances 0.000 description 1
• DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
• 229940081735 acetylcellulose Drugs 0.000 description 1
• 239000002253 acid Substances 0.000 description 1
• 150000001251 acridines Chemical class 0.000 description 1
• 231100000439 acute liver injury Toxicity 0.000 description 1
• 230000001464 adherent effect Effects 0.000 description 1
• 239000000443 aerosol Substances 0.000 description 1
• 239000008272 agar Substances 0.000 description 1
• 235000010419 agar Nutrition 0.000 description 1
• 229940040563 agaric acid Drugs 0.000 description 1
• 239000000556 agonist Substances 0.000 description 1
• 150000001298 alcohols Chemical class 0.000 description 1
• 235000010443 alginic acid Nutrition 0.000 description 1
• 239000000783 alginic acid Substances 0.000 description 1
• 229920000615 alginic acid Polymers 0.000 description 1
• 229960001126 alginic acid Drugs 0.000 description 1
• 150000004781 alginic acids Chemical class 0.000 description 1
• 125000003282 alkyl amino group Chemical group 0.000 description 1
• 125000005600 alkyl phosphonate group Chemical group 0.000 description 1
• 230000002152 alkylating effect Effects 0.000 description 1
• 230000004075 alteration Effects 0.000 description 1
• 125000003277 amino group Chemical group 0.000 description 1
• 125000002431 aminoalkoxy group Chemical group 0.000 description 1
• 125000005122 aminoalkylamino group Chemical group 0.000 description 1
• 239000000908 ammonium hydroxide Substances 0.000 description 1
• 230000037005 anaesthesia Effects 0.000 description 1
• 238000010171 animal model Methods 0.000 description 1
• 238000000137 annealing Methods 0.000 description 1
• 230000001567 anti-fibrinolytic effect Effects 0.000 description 1
• 229930185229 antidesmin Natural products 0.000 description 1
• 239000000427 antigen Substances 0.000 description 1
• 102000036639 antigens Human genes 0.000 description 1
• 108091007433 antigens Proteins 0.000 description 1
• 229940027998 antiseptic and disinfectant acridine derivative Drugs 0.000 description 1
• 230000003305 autocrine Effects 0.000 description 1
• 239000003833 bile salt Substances 0.000 description 1
• 229940093761 bile salts Drugs 0.000 description 1
• 230000004071 biological effect Effects 0.000 description 1
• 230000033228 biological regulation Effects 0.000 description 1
• 230000017531 blood circulation Effects 0.000 description 1
• 210000004556 brain Anatomy 0.000 description 1
• FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 description 1
• 235000011010 calcium phosphates Nutrition 0.000 description 1
• 239000008116 calcium stearate Substances 0.000 description 1
• 235000013539 calcium stearate Nutrition 0.000 description 1
• 238000004364 calculation method Methods 0.000 description 1
• 125000001369 canonical nucleoside group Chemical group 0.000 description 1
• 239000004202 carbamide Substances 0.000 description 1
• 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
• 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
• 239000003054 catalyst Substances 0.000 description 1
• 125000002091 cationic group Chemical group 0.000 description 1
• 230000022131 cell cycle Effects 0.000 description 1
• 230000012292 cell migration Effects 0.000 description 1
• 230000004700 cellular uptake Effects 0.000 description 1
• 238000005119 centrifugation Methods 0.000 description 1
• 125000003636 chemical group Chemical group 0.000 description 1
• 235000012000 cholesterol Nutrition 0.000 description 1
• BHQCQFFYRZLCQQ-OELDTZBJSA-N cholic acid Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 BHQCQFFYRZLCQQ-OELDTZBJSA-N 0.000 description 1
• 235000019416 cholic acid Nutrition 0.000 description 1
• 229960002471 cholic acid Drugs 0.000 description 1
• 230000001684 chronic effect Effects 0.000 description 1
• 208000020832 chronic kidney disease Diseases 0.000 description 1
• 231100000012 chronic liver injury Toxicity 0.000 description 1
• 230000004087 circulation Effects 0.000 description 1
• 238000010367 cloning Methods 0.000 description 1
• 230000035602 clotting Effects 0.000 description 1
• 238000000205 computational method Methods 0.000 description 1
• 238000010276 construction Methods 0.000 description 1
• 239000005289 controlled pore glass Substances 0.000 description 1
• 210000004351 coronary vessel Anatomy 0.000 description 1
• 230000001351 cycling effect Effects 0.000 description 1
• 230000007812 deficiency Effects 0.000 description 1
• 238000012217 deletion Methods 0.000 description 1
• 230000037430 deletion Effects 0.000 description 1
• KXGVEGMKQFWNSR-UHFFFAOYSA-N deoxycholic acid Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)C(O)C2 KXGVEGMKQFWNSR-UHFFFAOYSA-N 0.000 description 1
• VGONTNSXDCQUGY-UHFFFAOYSA-N desoxyinosine Natural products C1C(O)C(CO)OC1N1C(NC=NC2=O)=C2N=C1 VGONTNSXDCQUGY-UHFFFAOYSA-N 0.000 description 1
• 238000001514 detection method Methods 0.000 description 1
• 230000001627 detrimental effect Effects 0.000 description 1
• 229960002086 dextran Drugs 0.000 description 1
• 229960000633 dextran sulfate Drugs 0.000 description 1
• 208000033679 diabetic kidney disease Diseases 0.000 description 1
• NEFBYIFKOOEVPA-UHFFFAOYSA-K dicalcium phosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])([O-])=O NEFBYIFKOOEVPA-UHFFFAOYSA-K 0.000 description 1
• 235000019700 dicalcium phosphate Nutrition 0.000 description 1
• 229910000390 dicalcium phosphate Inorganic materials 0.000 description 1
• 229940038472 dicalcium phosphate Drugs 0.000 description 1
• RNPXCFINMKSQPQ-UHFFFAOYSA-N dicetyl hydrogen phosphate Chemical compound CCCCCCCCCCCCCCCCOP(O)(=O)OCCCCCCCCCCCCCCCC RNPXCFINMKSQPQ-UHFFFAOYSA-N 0.000 description 1
• 229940093541 dicetylphosphate Drugs 0.000 description 1
• 230000029087 digestion Effects 0.000 description 1
• 239000003085 diluting agent Substances 0.000 description 1
• 238000012377 drug delivery Methods 0.000 description 1
• 230000002500 effect on skin Effects 0.000 description 1
• 238000004520 electroporation Methods 0.000 description 1
• 238000013156 embolectomy Methods 0.000 description 1
• 239000000839 emulsion Substances 0.000 description 1
• 201000000523 end stage renal failure Diseases 0.000 description 1
• 230000002708 enhancing effect Effects 0.000 description 1
• 230000007515 enzymatic degradation Effects 0.000 description 1
• 238000006911 enzymatic reaction Methods 0.000 description 1
• YQGOJNYOYNNSMM-UHFFFAOYSA-N eosin Chemical compound [Na+].OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 YQGOJNYOYNNSMM-UHFFFAOYSA-N 0.000 description 1
• LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
• 229940093471 ethyl oleate Drugs 0.000 description 1
• 150000004665 fatty acids Chemical class 0.000 description 1
• 150000002191 fatty alcohols Chemical class 0.000 description 1
• 230000003480 fibrinolytic effect Effects 0.000 description 1
• 239000000945 filler Substances 0.000 description 1
• 239000012530 fluid Substances 0.000 description 1
• 229960002143 fluorescein Drugs 0.000 description 1
• 201000005206 focal segmental glomerulosclerosis Diseases 0.000 description 1
• 231100000854 focal segmental glomerulosclerosis Toxicity 0.000 description 1
• 238000013467 fragmentation Methods 0.000 description 1
• 238000006062 fragmentation reaction Methods 0.000 description 1
• 238000002825 functional assay Methods 0.000 description 1
• 230000004927 fusion Effects 0.000 description 1
• 230000002068 genetic effect Effects 0.000 description 1
• 239000008187 granular material Substances 0.000 description 1
• 230000012010 growth Effects 0.000 description 1
• 238000010438 heat treatment Methods 0.000 description 1
• 230000000004 hemodynamic effect Effects 0.000 description 1
• 125000004404 heteroalkyl group Chemical group 0.000 description 1
• 125000000592 heterocycloalkyl group Chemical group 0.000 description 1
• 150000002402 hexoses Chemical class 0.000 description 1
• 230000009215 host defense mechanism Effects 0.000 description 1
• 102000046661 human PECAM1 Human genes 0.000 description 1
• 229920002674 hyaluronan Polymers 0.000 description 1
• 229960003160 hyaluronic acid Drugs 0.000 description 1
• AFQIYTIJXGTIEY-UHFFFAOYSA-N hydrogen carbonate;triethylazanium Chemical compound OC(O)=O.CCN(CC)CC AFQIYTIJXGTIEY-UHFFFAOYSA-N 0.000 description 1
• 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
• WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
• 230000002055 immunohistochemical effect Effects 0.000 description 1
• 238000012744 immunostaining Methods 0.000 description 1
• 230000001771 impaired effect Effects 0.000 description 1
• 239000007943 implant Substances 0.000 description 1
• 238000011065 in-situ storage Methods 0.000 description 1
• 230000000415 inactivating effect Effects 0.000 description 1
• 208000015181 infectious disease Diseases 0.000 description 1
• 210000004969 inflammatory cell Anatomy 0.000 description 1
• 238000001802 infusion Methods 0.000 description 1
• 239000003999 initiator Substances 0.000 description 1
• 210000002570 interstitial cell Anatomy 0.000 description 1
• 238000001361 intraarterial administration Methods 0.000 description 1
• 239000007927 intramuscular injection Substances 0.000 description 1
• 238000010255 intramuscular injection Methods 0.000 description 1
• 239000007928 intraperitoneal injection Substances 0.000 description 1
• 238000010253 intravenous injection Methods 0.000 description 1
• 238000004255 ion exchange chromatography Methods 0.000 description 1
• 239000002563 ionic surfactant Substances 0.000 description 1
• 208000028867 ischemia Diseases 0.000 description 1
• 229960003299 ketamine Drugs 0.000 description 1
• 201000006370 kidney failure Diseases 0.000 description 1
• 238000011813 knockout mouse model Methods 0.000 description 1
• 239000004922 lacquer Substances 0.000 description 1
• 230000002045 lasting effect Effects 0.000 description 1
• 235000010445 lecithin Nutrition 0.000 description 1
• 239000000787 lecithin Substances 0.000 description 1
• 229940067606 lecithin Drugs 0.000 description 1
• 210000000265 leukocyte Anatomy 0.000 description 1
• 239000003446 ligand Substances 0.000 description 1
• 229940057995 liquid paraffin Drugs 0.000 description 1
• MHCFAGZWMAWTNR-UHFFFAOYSA-M lithium perchlorate Chemical compound [Li+].[O-]Cl(=O)(=O)=O MHCFAGZWMAWTNR-UHFFFAOYSA-M 0.000 description 1
• 229910001486 lithium perchlorate Inorganic materials 0.000 description 1
• 210000005229 liver cell Anatomy 0.000 description 1
• 238000011068 loading method Methods 0.000 description 1
• 230000033001 locomotion Effects 0.000 description 1
• 239000006210 lotion Substances 0.000 description 1
• 230000001050 lubricating effect Effects 0.000 description 1
• 206010025135 lupus erythematosus Diseases 0.000 description 1
• 239000012139 lysis buffer Substances 0.000 description 1
• 239000000594 mannitol Substances 0.000 description 1
• 235000010355 mannitol Nutrition 0.000 description 1
• 229910052751 metal Inorganic materials 0.000 description 1
• 239000002184 metal Substances 0.000 description 1
• 229930182817 methionine Natural products 0.000 description 1
• 229920000609 methyl cellulose Polymers 0.000 description 1
• 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
• 239000001923 methylcellulose Substances 0.000 description 1
• 235000010981 methylcellulose Nutrition 0.000 description 1
• 239000004530 micro-emulsion Substances 0.000 description 1
• 239000004005 microsphere Substances 0.000 description 1
• 238000002156 mixing Methods 0.000 description 1
• 238000010369 molecular cloning Methods 0.000 description 1
• 238000007491 morphometric analysis Methods 0.000 description 1
• 208000029744 multiple organ dysfunction syndrome Diseases 0.000 description 1
• 210000002464 muscle smooth vascular Anatomy 0.000 description 1
• 208000031225 myocardial ischemia Diseases 0.000 description 1
• 210000000651 myofibroblast Anatomy 0.000 description 1
• 230000017074 necrotic cell death Effects 0.000 description 1
• 230000007935 neutral effect Effects 0.000 description 1
• 239000012457 nonaqueous media Substances 0.000 description 1
• 230000006911 nucleation Effects 0.000 description 1
• 238000010899 nucleation Methods 0.000 description 1
• 239000002777 nucleoside Substances 0.000 description 1
• 125000003835 nucleoside group Chemical group 0.000 description 1
• QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
• OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
• 239000002674 ointment Substances 0.000 description 1
• 229940046166 oligodeoxynucleotide Drugs 0.000 description 1
• 210000000056 organ Anatomy 0.000 description 1
• 239000003960 organic solvent Substances 0.000 description 1
• 239000003791 organic solvent mixture Substances 0.000 description 1
• 125000001181 organosilyl group Chemical group [SiH3]* 0.000 description 1
• 238000012261 overproduction Methods 0.000 description 1
• 150000002926 oxygen Chemical class 0.000 description 1
• 125000004430 oxygen atom Chemical group O* 0.000 description 1
• 238000007911 parenteral administration Methods 0.000 description 1
• 230000001717 pathogenic effect Effects 0.000 description 1
• 239000008188 pellet Substances 0.000 description 1
• 229940049954 penicillin Drugs 0.000 description 1
• 239000000863 peptide conjugate Substances 0.000 description 1
• 210000003516 pericardium Anatomy 0.000 description 1
• 108040007629 peroxidase activity proteins Proteins 0.000 description 1
• 210000001539 phagocyte Anatomy 0.000 description 1
• 230000000144 pharmacologic effect Effects 0.000 description 1
• 235000021317 phosphate Nutrition 0.000 description 1
• 150000003904 phospholipids Chemical class 0.000 description 1
• 150000008298 phosphoramidates Chemical class 0.000 description 1
• 150000003014 phosphoric acid esters Chemical class 0.000 description 1
• 230000026731 phosphorylation Effects 0.000 description 1
• 238000006366 phosphorylation reaction Methods 0.000 description 1
• 102000020233 phosphotransferase Human genes 0.000 description 1
• 230000000704 physical effect Effects 0.000 description 1
• 239000000049 pigment Substances 0.000 description 1
• 239000013612 plasmid Substances 0.000 description 1
• 239000004014 plasticizer Substances 0.000 description 1
• 229920002647 polyamide Polymers 0.000 description 1
• 229950005134 polycarbophil Drugs 0.000 description 1
• 229920000570 polyether Polymers 0.000 description 1
• 229920000573 polyethylene Polymers 0.000 description 1
• 229920000656 polylysine Polymers 0.000 description 1
• 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
• 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
• 238000010837 poor prognosis Methods 0.000 description 1
• 230000004481 post-translational protein modification Effects 0.000 description 1
• 229920001592 potato starch Polymers 0.000 description 1
• 229940124606 potential therapeutic agent Drugs 0.000 description 1
• 239000000843 powder Substances 0.000 description 1
• 230000000019 pro-fibrinolytic effect Effects 0.000 description 1
• 108090000765 processed proteins & peptides Proteins 0.000 description 1
• 238000012545 processing Methods 0.000 description 1
• 239000003805 procoagulant Substances 0.000 description 1
• 230000002947 procoagulating effect Effects 0.000 description 1
• 229960000286 proflavine Drugs 0.000 description 1
• 230000002250 progressing effect Effects 0.000 description 1
• 230000001737 promoting effect Effects 0.000 description 1
• 230000000069 prophylactic effect Effects 0.000 description 1
• 235000019833 protease Nutrition 0.000 description 1
• 230000001681 protective effect Effects 0.000 description 1
• 230000002797 proteolythic effect Effects 0.000 description 1
• ZCCUUQDIBDJBTK-UHFFFAOYSA-N psoralen Chemical class C1=C2OC(=O)C=CC2=CC2=C1OC=C2 ZCCUUQDIBDJBTK-UHFFFAOYSA-N 0.000 description 1
• 230000005180 public health Effects 0.000 description 1
• 208000005069 pulmonary fibrosis Diseases 0.000 description 1
• 238000000746 purification Methods 0.000 description 1
• 150000003230 pyrimidines Chemical class 0.000 description 1
• 230000002285 radioactive effect Effects 0.000 description 1
• 230000009257 reactivity Effects 0.000 description 1
• 230000008707 rearrangement Effects 0.000 description 1
• 238000011084 recovery Methods 0.000 description 1
• 230000007115 recruitment Effects 0.000 description 1
• 230000002829 reductive effect Effects 0.000 description 1
• 230000008929 regeneration Effects 0.000 description 1
• 238000011069 regeneration method Methods 0.000 description 1
• 230000009076 regulation of hemostasis Effects 0.000 description 1
• 230000008085 renal dysfunction Effects 0.000 description 1
• 231100001028 renal lesion Toxicity 0.000 description 1
• 210000005084 renal tissue Anatomy 0.000 description 1
• 230000004043 responsiveness Effects 0.000 description 1
• 229940100486 rice starch Drugs 0.000 description 1
• 239000000523 sample Substances 0.000 description 1
• 229920006395 saturated elastomer Polymers 0.000 description 1
• 238000012163 sequencing technique Methods 0.000 description 1
• 239000012679 serum free medium Substances 0.000 description 1
• 230000035939 shock Effects 0.000 description 1
• 239000000377 silicon dioxide Substances 0.000 description 1
• 210000002460 smooth muscle Anatomy 0.000 description 1
• 230000015590 smooth muscle cell migration Effects 0.000 description 1
• 235000010413 sodium alginate Nutrition 0.000 description 1
• 239000000661 sodium alginate Substances 0.000 description 1
• 229940005550 sodium alginate Drugs 0.000 description 1
• 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
• 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
• 159000000000 sodium salts Chemical class 0.000 description 1
• 239000007901 soft capsule Substances 0.000 description 1
• 239000007787 solid Substances 0.000 description 1
• 230000009870 specific binding Effects 0.000 description 1
• 229940063675 spermine Drugs 0.000 description 1
• 230000002269 spontaneous effect Effects 0.000 description 1
• 238000013222 sprague-dawley male rat Methods 0.000 description 1
• 238000010561 standard procedure Methods 0.000 description 1
• 239000008117 stearic acid Substances 0.000 description 1
• 210000004500 stellate cell Anatomy 0.000 description 1
• 239000008223 sterile water Substances 0.000 description 1
• 150000003431 steroids Chemical class 0.000 description 1
• 230000004936 stimulating effect Effects 0.000 description 1
• 229960005322 streptomycin Drugs 0.000 description 1
• 238000007920 subcutaneous administration Methods 0.000 description 1
• 239000007929 subcutaneous injection Substances 0.000 description 1
• 238000005987 sulfurization reaction Methods 0.000 description 1
• 239000006228 supernatant Substances 0.000 description 1
• 208000011580 syndromic disease Diseases 0.000 description 1
• 230000008718 systemic inflammatory response Effects 0.000 description 1
• 125000003396 thiol group Chemical group [H]S* 0.000 description 1
• 239000004408 titanium dioxide Substances 0.000 description 1
• 230000000699 topical effect Effects 0.000 description 1
• 238000012546 transfer Methods 0.000 description 1
• 230000001131 transforming effect Effects 0.000 description 1
• 238000011269 treatment regimen Methods 0.000 description 1
• 229940078499 tricalcium phosphate Drugs 0.000 description 1
• 235000019731 tricalcium phosphate Nutrition 0.000 description 1
• 229910000391 tricalcium phosphate Inorganic materials 0.000 description 1
• 238000000870 ultraviolet spectroscopy Methods 0.000 description 1
• 210000003606 umbilical vein Anatomy 0.000 description 1
• 241001430294 unidentified retrovirus Species 0.000 description 1
• 230000003827 upregulation Effects 0.000 description 1
• 229940035893 uracil Drugs 0.000 description 1
• 230000002620 ureteric effect Effects 0.000 description 1
• 102000009816 urokinase plasminogen activator receptor activity proteins Human genes 0.000 description 1
• 108040001269 urokinase plasminogen activator receptor activity proteins Proteins 0.000 description 1
• 230000002792 vascular Effects 0.000 description 1
• 210000003556 vascular endothelial cell Anatomy 0.000 description 1
• 210000003462 vein Anatomy 0.000 description 1
• 230000007998 vessel formation Effects 0.000 description 1
• 229920002554 vinyl polymer Polymers 0.000 description 1
• 201000001862 viral hepatitis Diseases 0.000 description 1
• 238000005406 washing Methods 0.000 description 1
• XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
• 230000007279 water homeostasis Effects 0.000 description 1
• 229940100445 wheat starch Drugs 0.000 description 1
• 230000029663 wound healing Effects 0.000 description 1
• BPICBUSOMSTKRF-UHFFFAOYSA-N xylazine Chemical compound CC1=CC=CC(C)=C1NC1=NCCCS1 BPICBUSOMSTKRF-UHFFFAOYSA-N 0.000 description 1
• 229960001600 xylazine Drugs 0.000 description 1
• 239000008096 xylene Substances 0.000 description 1